21 August 2026
The following report – Sodium Valproate & Topiramate Monitoring Statistics to June 2026 has been published as part of the General Pharmaceutical Services and Prescribing Statistics for Northern Ireland publication schedule. This report, produced in accordance with the Code of Practice for Statistics, contributes to the monitoring of the effectiveness of actions to ensure safe and appropriate use of prescribed Sodium Valproate and Topiramate in Northern Ireland.
This quarterly series combines the previously separate reports of Sodium Valproate and Topiramate monitoring into a singular release, with two sets of tables and a single interactive dashboard and can be accessed on the BSO website by clicking on the following link: Sodium Valproate & Topiramate Monitoring – Business Services Organisation (BSO) Website
The Sodium Valproate and Topiramate Monitoring Dashboard presents the figures of the five indicators contained within the published tables in interactive visuals. This interactive dashboard allows users to easily select between medicine of interest and numerous variables in order to focus on specific areas of interest, such as age group, gender or area in each of the five indicators.
To view the full report: Sodium Valproate & Topiramate Monitoring – Business Services Organisation (BSO) Website
A key facts summary of the main findings of each report is below.
